New drug duo tested for Tough-to-Treat neuroendocrine cancers
NCT ID NCT03290079
Summary
This study tested whether combining two existing cancer drugs, pembrolizumab and lenvatinib, could help control advanced neuroendocrine tumors that had worsened despite prior treatments. It involved 20 adults whose cancer had spread and was growing. The main goals were to see if the combination could shrink tumors, delay cancer growth, and was safe for patients to take.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.